全文获取类型
收费全文 | 100178篇 |
免费 | 6346篇 |
国内免费 | 433篇 |
专业分类
耳鼻咽喉 | 1112篇 |
儿科学 | 2510篇 |
妇产科学 | 1782篇 |
基础医学 | 12469篇 |
口腔科学 | 1747篇 |
临床医学 | 10620篇 |
内科学 | 20162篇 |
皮肤病学 | 1338篇 |
神经病学 | 10062篇 |
特种医学 | 3896篇 |
外国民族医学 | 3篇 |
外科学 | 16331篇 |
综合类 | 1081篇 |
一般理论 | 131篇 |
预防医学 | 8197篇 |
眼科学 | 2075篇 |
药学 | 6480篇 |
中国医学 | 105篇 |
肿瘤学 | 6856篇 |
出版年
2023年 | 500篇 |
2022年 | 769篇 |
2021年 | 2092篇 |
2020年 | 1325篇 |
2019年 | 2098篇 |
2018年 | 2548篇 |
2017年 | 1824篇 |
2016年 | 1986篇 |
2015年 | 2275篇 |
2014年 | 3443篇 |
2013年 | 4725篇 |
2012年 | 7563篇 |
2011年 | 7975篇 |
2010年 | 4583篇 |
2009年 | 4131篇 |
2008年 | 7125篇 |
2007年 | 7447篇 |
2006年 | 7176篇 |
2005年 | 6892篇 |
2004年 | 6717篇 |
2003年 | 6048篇 |
2002年 | 5705篇 |
2001年 | 839篇 |
2000年 | 558篇 |
1999年 | 891篇 |
1998年 | 1222篇 |
1997年 | 924篇 |
1996年 | 750篇 |
1995年 | 685篇 |
1994年 | 590篇 |
1993年 | 578篇 |
1992年 | 441篇 |
1991年 | 404篇 |
1990年 | 322篇 |
1989年 | 291篇 |
1988年 | 277篇 |
1987年 | 277篇 |
1986年 | 241篇 |
1985年 | 277篇 |
1984年 | 305篇 |
1983年 | 252篇 |
1982年 | 333篇 |
1981年 | 281篇 |
1980年 | 221篇 |
1979年 | 93篇 |
1978年 | 127篇 |
1977年 | 106篇 |
1976年 | 78篇 |
1975年 | 66篇 |
1973年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
931.
932.
933.
Die Anaesthesiologie - 相似文献
934.
Type 1 diabetes (T1D) is characterized by insulin deficiency resulting from the selective destruction of pancreatic β-cells by self-reactive T cells. Recent evidence demonstrates that innate immune responses substantially contribute to the pathogenesis of T1D, as they represent a first line of response to danger/damage signals. Here we discuss evidence on how, in a relapsing-remitting pattern, pancreas remodeling, diet, microbiota, gut permeability, and viral/bacterial infections induce the accumulation of leukocytes of the innate arm of the immune system throughout the pancreas. The subsequent acquisition and presentation of endocrine and exocrine antigens to the adaptive arm of the immune system results in a chronic progression of pancreatic damage. This process provides for the generation of self-reactive T-cell responses; however, the relative weight that genetic and environmental factors have on the etiopathogenesis of T1D is endotype imprinted and patient specific. With this Perspectives in Diabetes, our goal is to encourage the scientific community to rethink mechanisms underlying T1D pathogenesis and to consider therapeutic approaches that focus on these processes in intervention trials within new-onset disease as well as in efforts seeking the disorder’s prevention in individuals at high risk. 相似文献
935.
Andrea Lin Jasmine A. Mack Brittany Bruggeman Laura M. Jacobsen Amanda L. Posgai Clive H. Wasserfall Todd M. Brusko Mark A. Atkinson Stephen E. Gitelman Peter A. Gottlieb Matthew J. Gurka Clayton E. Mathews Desmond A. Schatz Michael J. Haller 《Diabetes》2021,70(5):1123
Previously, we demonstrated low-dose antithymocyte globulin (ATG) and granulocyte colony-stimulating factor (GCSF) immunotherapy preserved C-peptide for 2 years in a pilot study of patients with established type 1 diabetes (n = 25). Here, we evaluated the long-term outcomes of ATG/GCSF in study participants with 5 years of available follow-up data (n = 15). The primary end point was area under the curve (AUC) C-peptide during a 2-h mixed-meal tolerance test. After 5 years, there were no statistically significant differences in AUC C-peptide when comparing those who received ATG/GCSF versus placebo (P = 0.41). A modeling framework based on mean trajectories in C-peptide AUC over 5 years, accounting for differing trends between groups, was applied to recategorize responders (n = 9) and nonresponders (n = 7). ATG/GCSF reponders demonstrated nearly unchanged HbA1c over 5 years (mean [95% CI] adjusted change 0.29% [–0.69%, 1.27%]), but the study was not powered for comparisons against nonresponders 1.75% (–0.57%, 4.06%) or placebo recipients 1.44% (0.21%, 2.66%). These data underscore the importance of long-term follow-up in previous and ongoing phase 2 trials of low-dose ATG in recent-onset type 1 diabetes. 相似文献
936.
937.
Fabio Casciani Maxwell T. Trudeau Horacio J. Asbun Chad G. Ball Claudio Bassi Stephen W. Behrman Adam C. Berger Mark P. Bloomston Mark P. Callery John D. Christein Massimo Falconi Carlos Fernandez-del Castillo Mary E. Dillhoff Euan J. Dickson Elijah Dixon William E. Fisher Michael G. House Steven J. Hughes John W. Kunstman 《Surgery》2021,169(4):708-720
BackgroundPancreatoduodenectomies at high risk for clinically relevant pancreatic fistula are uncommon, yet intimidating, situations. In such scenarios, the impact of individual surgeon experience on outcomes is poorly understood.MethodsThe fistula risk score was applied to identify high-risk patients (fistula risk score 7–10) from 7,706 pancreatoduodenectomies performed at 18 international institutions (2003–2020). For each case, surgeon pancreatoduodenectomy career volume and years of practice were linked to intraoperative fistula mitigation strategy adoption and outcomes. Consequently, best operative approaches for clinically relevant pancreatic fistula prevention and best performer profiles were identified through multivariable analysis models.ResultsEight hundred and thirty high-risk pancreatoduodenectomies, performed by 64 surgeons, displayed an overall clinically relevant pancreatic fistula rate of 33.7%. Clinically relevant pancreatic fistula rates decreased with escalating surgeon career pancreatoduodenectomy (–49.7%) and career length (–41.2%; both P < .001), as did transfusion and reoperation rates, postoperative morbidity index, and duration of stay. Great experience (≥400 pancreatoduodenectomies performed or ≥21-year-long career) was a significant predictor of clinically relevant pancreatic fistula prevention (odds ratio 0.52, 95% confidence interval 0.35–0.76) and was more often associated with pancreatojejunostomy reconstruction and prophylactic octreotide omission, which were both independently associated with clinically relevant pancreatic fistula reduction. A risk-adjusted performance analysis also correlated with experience. Moreover, minimizing blood loss (≤400 mL) significantly contributed to clinically relevant pancreatic fistula prevention (odds ratio 0.40, 95% confidence interval 0.22–0.74).ConclusionSurgeon experience is a key contributor to achieve better outcomes after high-risk pancreatoduodenectomy. Surgeons can improve their performance in these challenging situations by employing pancreatojejunostomy reconstruction, omitting prophylactic octreotide, and minimizing blood loss. 相似文献
938.
Carlos R Ferreira Dillon Kavanagh Ralf Oheim Kristin Zimmerman Julian Stürznickel Xiaofeng Li Paul Stabach R Luke Rettig Logan Calderone Colin MacKichan Aaron Wang Hunter A Hutchinson Tracy Nelson Steven M Tommasini Simon von Kroge Imke AK Fiedler Ethan R Lester Gilbert W Moeckel Björn Busse Thorsten Schinke Thomas O Carpenter Michael A Levine Mark C Horowitz Demetrios T Braddock 《Journal of bone and mineral research》2021,36(5):942-955
Inactivating mutations in human ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) may result in early-onset osteoporosis (EOOP) in haploinsufficiency and autosomal recessive hypophosphatemic rickets (ARHR2) in homozygous deficiency. ARHR2 patients are frequently treated with phosphate supplementation to ameliorate the rachitic phenotype, but elevating plasma phosphorus concentrations in ARHR2 patients may increase the risk of ectopic calcification without increasing bone mass. To assess the risks and efficacy of conventional ARHR2 therapy, we performed comprehensive evaluations of ARHR2 patients at two academic medical centers and compared their skeletal and renal phenotypes with ENPP1-deficient Enpp1asj/asj mice on an acceleration diet containing high phosphate treated with recombinant murine Enpp1-Fc. ARHR2 patients treated with conventional therapy demonstrated improvements in rickets, but all adults and one adolescent analyzed continued to exhibit low bone mineral density (BMD). In addition, conventional therapy was associated with the development of medullary nephrocalcinosis in half of the treated patients. Similar to Enpp1asj/asj mice on normal chow and to patients with mono- and biallelic ENPP1 mutations, 5-week-old Enpp1asj/asj mice on the high-phosphate diet exhibited lower trabecular bone mass, reduced cortical bone mass, and greater bone fragility. Treating the Enpp1asj/asj mice with recombinant Enpp1-Fc protein between weeks 2 and 5 normalized trabecular bone mass, normalized or improved bone biomechanical properties, and prevented the development of nephrocalcinosis and renal failure. The data suggest that conventional ARHR2 therapy does not address low BMD inherent in ENPP1 deficiency, and that ENPP1 enzyme replacement may be effective for correcting low bone mass in ARHR2 patients without increasing the risk of nephrocalcinosis. © 2021 American Society for Bone and Mineral Research (ASBMR). 相似文献
939.